CD274 and neoplasm: In summary, TPP‐LND@Lip, constructed by a simple and economical method, solved the systemic adverse reactions and insufficient efficacy of traditional PD‐L1 antibodies and could be used as a new strategy for tumor‐targeted regulation of PD‐L1.